WS15: Leukaemia (15-May-2001)
Series
History of Modern Biomedicine Witness Seminars (Photo Collection);eWS15.01
History of Modern Biomedicine Witness Seminars (Photo Collection);eWS15.02
History of Modern Biomedicine Witness Seminars (Photo Collection);eWS15.03
Metadata
Show full item recordAbstract
Selection of photos taken at the Witness Seminar “Leukaemia” held by the History of Twentieth Century Medicine Group, 15-May-2001. Participants: Sir Christopher Booth, Professor Daniel Catovsky, Professor Derek Crowther, Professor David Galton, Professor John Goldman (Chair), Dr David Grant, Professor Frank Hayhoe, Professor Victor Hoffbrand, Dr Peter Hunter, Professor Humphrey Kay, Professor Sir John Lilleyman, Professor Ian MacLennan, Dr Gordon Piller, Professor Ray Powles, Dr Rosemary Shannon, Dr John Stock, Dr Tilli Tansey, Professor John Walker-Smith, and Dr Eve Wiltshaw.
Authors
History of Twentieth Century Medicine Group
History of Modern Biomedicine Research Group
Collections
Licence information
Related items
Showing items related by title, author, creator and subject.
-
Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Davies, JK; Hassan, S; Sarker, S-J; Besley, C; Oakervee, H; Smith, M; Taussig, D; Gribben, JG; Cavenagh, JD (2018-02)Allogeneic haematopoietic stem-cell transplantation remains the only curative treatment for relapsed/refractory acute myeloid leukaemia (AML) and high-risk myelodysplasia but has previously been limited to patients who ... -
The Genomics of Acute Myeloid Leukaemia An Investigation into the Molecular Pathogenesis of Acute Myeloid Leukaemia with t(8;21)
Mannari, Deepak (Queen Mary University of London, 2012)Acute myeloid leukaemia is a clonal disorder characterised by recurrent chromosomal translocations. One of the commonest, is the t(8;21) which results in part of the AML1 gene being juxtaposed to most of the ETO gene ... -
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
Korfi, K; Mandal, A; Furney, SJ; Wiseman, D; Somervaille, TCP; Marais, R (2015-06)